Literature DB >> 1666496

In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.

E L Hill1, G A Hunter, M N Ellis.   

Abstract

A total of 100 herpes simplex viruses isolated from lesions not responding to acyclovir (ACV) therapy were recovered from 51 patients infected with human immunodeficiency virus. In vitro analysis of these isolates included testing their susceptibility to ACV and determining their thymidine kinase (TK) phenotypes. Of the 100 isolates evaluated, 23 were ACV sensitive and 77 were ACV resistant. Seventy-four of these ACV-resistant isolates were of the TK-deficient or low-TK-producer phenotype and three were of the TK-altered phenotype. The TKs isolates that represented each of the different autoradiographic phenotypes were further characterized by enzyme kinetics. The ability of selected isolates to cause disease in vivo was evaluated by using several mouse virulence models. Cutaneous virulence in normal and immunocompromised mice was evaluated, and neurovirulence in normal mice was determined. Latent infections were assayed by the cocultivation of trigeminal ganglia recovered from mice that had survived acute infection. These reactivated viruses were evaluated in vitro and compared with the original infecting isolate. The mechanisms of resistance and pathogenicity of these herpes simplex virus isolates recovered from patients positive for human immunodeficiency virus are similar to those reported for isolates recovered from normal and immunocompromised patients without AIDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666496      PMCID: PMC245379          DOI: 10.1128/AAC.35.11.2322

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Selective assay for herpes simplex viruses expressing thymidine kinase.

Authors:  J Campione-Piccardo; W E Rawls; S Bacchetti
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

2.  Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy.

Authors:  W H Burns; R Saral; G W Santos; O L Laskin; P S Lietman; C McLaren; D W Barry
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

3.  A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents.

Authors:  C McLaren; M N Ellis; G A Hunter
Journal:  Antiviral Res       Date:  1983-11       Impact factor: 5.970

4.  Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.

Authors:  S E Straus; H E Takiff; M Seidlin; S Bachrach; L Lininger; J J DiGiovanna; K A Western; H A Smith; S N Lehrman; T Creagh-Kirk
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

Review 5.  Virus resistance in clinical practice.

Authors:  C Dekker; M N Ellis; C McLaren; G Hunter; J Rogers; D W Barry
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

6.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

7.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

Authors:  D M Coen; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  Treatment of resistant herpes simplex virus with continuous-infusion acyclovir.

Authors:  J P Engel; J A Englund; C V Fletcher; E L Hill
Journal:  JAMA       Date:  1990 Mar 23-30       Impact factor: 56.272

9.  Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities.

Authors:  P A Furman; D M Coen; M H St Clair; P A Schaffer
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

10.  In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients.

Authors:  C McLaren; L Corey; C Dekket; D W Barry
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

View more
  22 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

Review 3.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 5.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

9.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

10.  Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia.

Authors:  Kening Wang; Gowtham Mahalingam; Susan E Hoover; Erik K Mont; Steven M Holland; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.